GDF15 Antikörper (C-Term)

Produktnummer ABIN453961

Der Kaninchen Polyklonal anti-GDF15 Antikörper wird verwendet zum Nachweis von GDF15 in Proben von Human, Maus, Ratte, Schimpanse und Makake. Er wurde validiert für WB und EIA.

Kurzübersicht für GDF15 Antikörper (C-Term) (ABIN453961)

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Reaktivität: Human, Maus, Ratte, Schimpanse, Makake

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser GDF15 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-GDF15 Antikörper

Bindungsspezifität: C-Term

Spezifität: This antibody reacts with the C-terminus of endogenous NAG-1 protein.

Kreuzreaktivität (Details): Species reactivity (expected):Chimpanzee, Macaque, Mouse, Rat.
Species reactivity (tested):Human.

Aufreinigung: Affinity chromatography

Immunogen: Synthetic peptide corresponding to the C-terminal sequence of NAG-1 protein. A residue of cysteine was added to facilitate coupling

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA: 1/300,000. Western Blot: 2,000 - 10,000.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.0 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.09 % (w/v) Sodium

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Details zu GDF15

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Andere Bezeichnung: GDF15

Hintergrund: The non-steroidal antiinflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. The induced expression of NAG-1 results in a stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.Synonyms: GDF-15, Growth/differentiation factor 15, MIC-1, MIC1, Macrophage inhibitory cytokine 1, NAG-1, NRG-1, NSAID-activated gene 1 protein, NSAID-regulated gene 1 protein, PDF, PLAB, PTGFB, Placental TGF-beta, Placental bone morphogenetic protein, Prostate differentiation factor

Gen-ID: 9518

NCBI Accession: NP_004855

UniProt: Q99988

Pathways: SARS-CoV-2 Protein Interaktom